NDA Resubmission, Accelerated Assessment of Marketing Application, and Esteemed Recognition - Analyst Notes on McKesson, AbbVie, Lilly, Zoetis and Salix
PR Newswire - 21 mins ago
Today, Analysts Review released its analysts' notes regarding McKesson Corporation (NYSE: MCK), AbbVie Inc. (NYSE: ABBV), Eli Lilly and Company (NYSE: LLY), Zoetis Inc. (NYSE: ZTS) and Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3930-100free.
Shire Confirms Rejection of AbbVie Proposal
PR Newswire - 59 mins ago
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION
PR Newswire - Thu Jun 19, 10:48PM CDT
AbbVie Inc. ("AbbVie"
Better Stock Today Challenge: Philip Morris vs. AbbVie
Mark Reeth and David Williamson, The Motley Fool - Motley Fool - Thu Jun 19, 12:20PM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Philip Morris International takes on ...
AbbVie (ABBV) Declares 42c Quarterly Dividend
at The Street - Thu Jun 19, 10:50AM CDT
AbbVie (ABBV) declares a quarterly dividend of 42 cents a share, payable August 15 to shareholders of record as of July 15.
AbbVie Declares Quarterly Dividend
PR Newswire - Thu Jun 19, 10:28AM CDT
The board of directors of AbbVie Inc. (NYSE: ABBV) declared a quarterly cash dividend of $0.42 per share.
Is This the Next Blockbuster MS Treatment?
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Wed Jun 18, 4:30PM CDT
Biogen Idec and its partner AbbVie reported good late stage results for multiple sclerosis drug daclizumab. While some are concerned about the increase in serious infections and a higher relapse rate than its earlier study, it shouldn't stop the...
Biogen/AbbVie Presents Positive Data on Daclizumab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 4:03PM CDT
Biogen Idec (BIIB) and partner AbbVie (ABBV) announced positive top-line results from a phase III trial, DECIDE, on pipeline candidate, daclizumab.
Merck Backs Out of Endocyte Vintafolide Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 11:10AM CDT
Endocyte, Inc. (ECYT) announced that it has regained worldwide rights to oncology candidate, vintafolide, as Merck decided to discontinue its investment in the development of vintafolide.
Androgel Testosterone Lawsuit Website Launches at AndrogelTestosteroneLawsuits.com by Prominent National Product Safety Law Firm
PRWeb - Wed Jun 18, 3:05AM CDT
The Androgel Testosterone Lawsuits website is a new resource from national product and family safety attorneys at The Onder Law Firm. Based in St. Louis, these testosterone lawyers have also represented clients in major pharmaceutical, product liability, and personal injury lawsuits, and offer expertise in representing the interests of individuals and families against major corporations. Persons seeking information about filing an Androgel testosterone lawsuit related to heart attack or stroke may contact the firm for a free testosterone lawsuit case review through the new website.
Is This Gilead's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jun 17, 4:30PM CDT
It's not often that big name biotechs double their earnings year over year. Yet that's exactly what Gilead Sciences did in the first quarter of 2014 after posting record sales for its new hepatitis C drug Sovaldi. Sovaldi raked in a reported...
GW Pharma Up On Positive Data For Epilepsy Drug
at Investor's Business Daily - Tue Jun 17, 3:20PM CDT
British biotech GW Pharmaceuticals (GWPH) Tuesday reported positive safety and efficacy data from physicians treating epileptics with its drug Epidiolex, sending the stock up 16% to 89.82 on the stock market today . But shares gave up some of those...
Why This "Worst Deal" Could Work
Brian Wilson, The Motley Fool - Motley Fool - Tue Jun 17, 9:42AM CDT
Recently, the pharmaceutical giant Merck has been receiving a bit of heat from commentators who believe that the company offered way too much money for the hepatitis c therapeutics developer Idenix Pharmaceuticals last week. Although the...
2 Exciting Developments for Biogen Idec Inc.
Cheryl Swanson, The Motley Fool - Motley Fool - Tue Jun 17, 8:02AM CDT
Biogen , which just got nod from the FDA for its potential blockbuster hemophilia drug Eloctate last week, has also now cleared a major hurdle for a drug in its multiple sclerosis franchise. Joint developers Biogen and AbbVie announced Monday...
European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C
PR Newswire Europe - Tue Jun 17, 4:19AM CDT
AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA).
AbbVie Gets Priority Review from FDA for HCV Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 12:50PM CDT
AbbVie's (ABBV) experimental hepatitis C virus treatment could gain approval early in the fourth quarter of 2014.
Better Stock Today Challenge: Bank of America Corp vs. AbbVie
David Hanson and David Williamson, The Motley Fool - Motley Fool - Mon Jun 16, 11:22AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Bank of America takes on AbbVie for this...
Gilead's HCV Combination Therapy Data Looks Promising - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 16, 10:40AM CDT
Gilead Sciences (GILD) announced encouraging results from a phase III study on its HCV combination therapy of ledipasvir and Sovaldi .
Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis
Business Wire - Mon Jun 16, 6:30AM CDT
--a^' Positive Results Set Stage for Regulatory Filings -